The statistical analysis section is extremely sparse. What was the justification for the figures/numbers in the power and sample size calculation? This needs bolstered with a citation. There is no mention of multivariable modeling, but there is presentation of a multivariable model in the supplement. Please explain. I find it hard to believe that a RCT of this magnitude and planning would have such a limited statistics plan and this needs explained and expanded upon.
The fact that the protocol didn't really achieve its goal of raising StO2 is certainly a limitation and I'm glad that is mentioned by the authors. Either the protocol interventions were inappropriate or the target (StO2) was a bad target. Could the authors comment on whether they think that targeting the microcirculation is even a valid endpoint at this time?
The authors mention that red cell transfusion and dobutamine may have increased harm in the intervention arm, as represented by the mechanical ventilation differences. Were there differences in the amount of fluid resuscitation between the two arms? Please present these data. Due the explanation above, I consider this paper relevant for publication.
However, I would like to make following considerations: • I suggest includes in the text to be published more details about the procedure used, whit special highlight to the safety matter, which is clearly detailed in the supplementary material.
• Some recent studies have evaluated the method in cardiac surgical patients and have observed threshold values of 75%. On my view it could have influenced the need for transfusions and use of dobutamine. I suggest that this point could be added to the discussion.
•
The manuscript does not mention the new classification of sepsis (SEPSIS 3). Since there is more than a year that it has been published, I suggest explaining that this trial is before latest definitions.
• The same observations with regards the latest of the Surviving sepsis campaign published in the current year, even when the recommendations do not mentioned the microcirculation with resuscitation targets.
REVIEWER
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GENERAL COMMENTS
The investigators report a randomized controlled trial designed to assess the benefits and risks of targeting StO2 in adults with severe sepsis or septic shock.
The trial was conducted across 5 ICUs in France, Greece, Spain and Germany and enrolled 103 adults with underresuscitated severe sepsis and septic shock on ICU admission.
The experimental intervention consisted of a StO2 target above 80 % over at least 2 muscles compared to no StO2 target. The primary outcome combined 7-day mortality or worsening of SOFA between randomization and day 7.
The planned sample size was 190, based on an assumed a 50% control event rate and a 20% absolute risk reduction.
The data and safety monitoring board recommended stopping enrollment after the second interim analysis due to low recruitment rate and safety concern.
COMMENTS:
Internal validity The research question was relevant as the utility of adjusting resuscitation to surrogate endpoints is entrenched in usual practice despite sparse supportive evidence. Ascertaining the clinical impact of microvascular dysfunction as a resuscitation target was a meaningful objective.
Although the intervention could not be blinded, the trial was randomized, and randomization was concealed. As far as I could tell, the intention-to-treat principle was applied rigorously and every patient completed follow-up for the primary outcome.
The small size of the trial and the fact that it was interrupted early limit the internal validity of the results. The latter could be better emphasized in the discussion. Nonetheless, once the decision was made to interrupt the trial, I agree that the data should be published.
In explaining the difference in duration of mechanical ventilation, the authors raise the possibility that this is attributable to use of blood products and/or dobutamine, 2 interventions that have been associated with increased harm in the past. Please also report differences in IV fluid volume and actual MAP values while treated with vasopressors as there is recent evidence to suggest that more intense use of these additional therapies may be harmful.
Strength and precision of the results
The small size and early discontinuation of the trial constitutes a problem both for internal validity (increased risk of chance findings) and the precision of the results. As it is, the statistically significant difference in duration of mechanical ventilation doesn't exclude a trivial difference and the absence of a statistically significant difference in other outcomes doesn't rule out anything (i.e. the 95% CI are very wide). This should be expressed in lay terms in the discussion. Nonetheless, it is important to disseminate the results so that they may inform future research design or be integrated in evidence summaries in the future.
External validity AS mentioned by the authors, the resuscitation protocol used to achieve the StO2 targets reflects 2004 guidelines and is now outdated. The discussion could say more clearly that the results apply only to the combination of StO2 targets and this specific protocol.
Similarly, during the first 6 hours of the trial, there were no significant differences between the two study groups in any of the hemodynamic variables or lactate levels. StO2 were, at most, marginally reduced in the experimental arm and the only statistically significant difference could be due to multiple testing (Table 2) . The discussion appropriately distinguishes the issue of predictive validity of low StO2 from effectiveness of the interventions used in an attempt to raise StO2. Control -per KM curve -11, per table 3 -15 Not all of the endpoints listed in the report are listed in the paper. The secondary endpoints are listed were listed as 30 day mortality, ICU and hospital mortality, number of days alive and 1) off artificial ventilation, and ii) off catecholamines, and ICU and hospital length of stay. 11. Are the discussion and conclusions justified by the results? no Suggest start out with this sentence first -"The data and safety monitoring board recommended stopping enrollment after the second interim analysis due to low recruitment rate and safety concern. Although this study was underpowered to show an effect on the primary endpoint due to the premature early termination and difficulties encountered, it highlights practical issues to inform future studies." Other statements about the outcomes are questionable, unless there was enough power. 12. Are the study limitations discussed adequately? no No, the missing data was not mentioned in the results or in the study limitations. Also, a large percentage of the patients screened were excluded, this needs to be addressed. There is zero lost to follow up mentioned in the CONSORT -but the report says that there was one person who did not have SOFA score, and eight that did not have baseline score -was this data found after the report? 13. Is the supplmentary reporting complete (e.g. trial registration; funding details; CONSORT, STROBE or PRISMA checklist)? yes 14. To the best of your knowledge is the paper free from concerns over publication ethics (e.g. plagiarism, redundant publication, undeclared conflicts of interest)? no I am worried about the clinicaltrial.gov site not mentioning harm. 15. Is the standard of written English acceptable for publication? yes
REVIEWER

VERSION 1 -AUTHOR RESPONSE
Reviewer 1
The fact that the study was completed 8 years ago and has yet to be published makes one pause and ask why.
Response: The trial was terminated prematurely on May 2009 after enrollment of 105 patients, owing to the cessation of support from Hutchinson Technology. As a result of the 2009 global economic crisis, Hutchinson Technology was no more able to support the trial. Then,, we could obtain access to the database by March 2010, and the final statistical report was available by end of 2011. Thereafter, the study chair (Djillali Annane) joined the French government as the chief counselor for the Minister of Health from May 2012 to May 2017, a period during which he could not publish any paper in partnership with health product industry.
Comment: There is no stated hypothesis at the end of the Introduction.
Response: As clearly mentioned in trial protocol, the hypotheses were that patients with sepsis may benefit, on top of the Surviving Sepsis Campaign recommended protocolized resuscitation, from a strategy based on NIRS-measured muscles StO2 to guide optimization of tissues perfusion and oxygenation. This information is now given at the end of the "introduction" section of the manuscript. Response: Added in the statistical analysis paragraph Comment: I find it hard to believe that a RCT of this magnitude and planning would have such a limited statistics plan and this needs explained and expanded upon.
Response: supplementary appendix with the final protocol including trial's statistical plan Comment: The fact that the protocol didn't really achieve its goal of raising StO2 is certainly a limitation and I'm glad that is mentioned by the authors. Either the protocol interventions were inappropriate or the target (StO2) was a bad target. Could the authors comment on whether they think that targeting the microcirculation is even a valid endpoint at this time?
Response: As suggested by the reviewer, we have added a paragraph in the discussion section to underline that these findings do not exclude a potential benefit of targeting microcirculation in sepsis (see page 13, lines 8-18). This trial found that about 2/3 of patients with sepsis/septic shock had baseline StO2 levels <80% at two sites, whereas the vast majority had ScvO2 above 70%. These findings confirmed that abnormal StO2 may be a common feature in sepsis/septic shock. This trial found that including StO2>80% as a target in the algorithm for early goal directed therapy may have no added value in terms of clinical outcomes. However, these findings do not rule out a potential benefit of targeting StO2 in a different protocol based on different cut-off values, or different treatment strategy. Likewise, these findings did not rule out a potential benefit of targeting other surrogates of microcirculation. Since the trial was conducted the Surviving sepsis campaign guidelines have been updated twice. The 2016 updated guidelines still have no statement about targeting microcirculation in sepsis. In fact, while there are several technics that aim at measuring/monitoring microcirculation, no trial has so far investigated their usefulness to guide patient's resuscitation.
Comment: The authors mention that red cell transfusion and dobutamine may have increased harm in the intervention arm, as represented by the mechanical ventilation differences. Were there differences in the amount of fluid resuscitation between the two arms? Please present these data.
Response: There was no evidence for a statistically different amount of fluid therapy between the two groups. We have provided these data in the supplementary appendix (see table XXXX) Reviewer 2
Comment: This is an important study and even though it was essentially a negative trial and finished early it should be reported.
Response: Thank you
Comment: There are a number of minor English variations and punctuation errors to be fixed.
Response: The revised version of the manuscript has been copyedited by an English native person.
Comment: there is no mention of blinding by assessors Response: As stated in trial protocol: Allocation was concealed using sealed opaque enveloppes. (page 6 last line) In the control arm, St02 monitoring/recording was masked to ICU staff and trial's investigators. Outcomes were assessed in an unblinded manner. This information has been added in the revised manuscript, method section (see page 8, line 14)
Reviewer 3
Comment: I suggest includes in the text to be published more details about the procedure used, whit special highlight to the safety matter, which is clearly detailed in the supplementary material Response: Done as suggested Comment: Some recent studies have evaluated the method in cardiac surgical patients and have observed threshold values of 75%. On my view it could have influenced the need for transfusions and use of dobutamine. I suggest that this point could be added to the discussion.
Response: We have added a reference for cut-off values . As mentioned in the discussion section, the decision to use a cut-off of 80% was based on 1) reference values in healthy volunteers, 2) previous studies in sepsis suggesting that these cut-offs discriminated between survivor and nonsurvivors.
Comment: The manuscript does not mention the new classification of sepsis (SEPSIS 3). Since there is more than a year that it has been published, I suggest explaining that this trial is before latest definitions.
Response: As suggested, we have added a sentence in the discussion section to explain that this trial was conducted before the development of the new definitions for sepsis and septic shock (see page 13, line 13).
Comment: The same observations with regards the latest of the Surviving sepsis campaign published in the current year, even when the recommendations do not mentioned the microcirculation with resuscitation targets.
Response: As suggested, we have added a paragraph in the discussion section to underline that since the trial was conducted, there were two updates of Surviving sepsis campaign. The 2016 updated guidelines still have no statement about targeting microcirculation in sepsis (see page 13, lines 17-19).
Reviewer 4
Comment: The small size of the trial and the fact that it was interrupted early limit the internal validity of the results. The latter could be better emphasized in the discussion Response: The trial was designed to detect a 20% difference from a control value of 50%, in the composite outcome day-7 all cause-mortality or a day-7 SOFA score> to baseline SOFA score. Using bilateral test and considering a=5% and a power of 80%, 95 patients had to be included in each arm. The trial was terminated after enrollment of 103 patients, owing to the trial sponsor decision to stop supporting the trial. This decision was taken because the trial sponsor, Hutchinson technology, was strongly affected by the 2009 global economic crisis. Then, there were no way to continue to get the appropriate probes for monitoring StO2. We have added in the discussion section a paragraph explaining the reasons for the premature termination of the trial (see page 11, lines 3-10). We have also discussed the impact of this early discontinuation of the trial on its internal validity (see page 11). Nevertheless, the direction of the point estimate for the primary outcome did not favor the experimental intervention and there was a strong signal for harms in the analysis of the secondary outcomes. Thus, the likelihood that we missed a positive effect of the experimental intervention is very low. While, trials stopped prematurely for efficacy may result in overestimation of the effects of experimental intervention (ref), this trial was stopped as a consequence of the global economic crisis and not for treatment efficacy. The statistical plan did not include interim analysis.
Comment: In explaining the difference in duration of mechanical ventilation, the authors raise the possibility that this is attributable to use of blood products and/or dobutamine, 2 interventions that have been associated with increased harm in the past. Please also report differences in IV fluid volume and actual MAP values while treated with vasopressors as there is recent evidence to suggest that more intense use of these additional therapies may be harmful.
Response: There were no differences between groups according to the amount of fluid therapy, vasopressors, or MAP (see table supplemental files).
Comment: The small size and early discontinuation of the trial constitutes a problem both for internal validity (increased risk of chance findings) and the precision of the results. As it is, the statistically significant difference in duration of mechanical ventilation doesn't exclude a trivial difference and the absence of a statistically significant difference in other outcomes doesn't rule out anything (i.e. the 95% CI are very wide). This should be expressed in lay terms in the discussion.
Response: As mentioned above (see response to a previous comment from this reviewer) we have added in the discussion section a paragraph about the consequences of the early termination of the trial.
Comment: AS mentioned by the authors, the resuscitation protocol used to achieve the StO2 targets reflects 2004 guidelines and is now outdated. The discussion could say more clearly that the results apply only to the combination of StO2 targets and this specific protocol.
Response: Since the trial was conducted the Surviving sepsis campaign guidelines have been updated twice. The 2016 updated guidelines still have no statement about targeting microcirculation in sepsis. In fact, while there are several technics that aim at measuring/monitoring microcirculation, no trial has so far investigated their usefulness to guide patient's resuscitation. This is now mentioned in the discussion section (see page 13, lines 19) As suggested by the reviewer, we have added a paragraph in the discussion section to underline that these findings do not exclude a potential benefit of targeting microcirculation in sepsis . This trial found that about 2/3 of patients with sepsis/septic shock had baseline StO2 levels <80% at two sites, whereas the vast majority had ScvO2 above 70%. These findings confirmed that abnormal StO2 may be a common feature in sepsis/septic shock. This trial found that including StO2>80% as a target in the algorithm for early goal directed therapy (EGDT) may have no added value in terms of clinical outcomes. It also found that the common interventions linked to EGDT did not allow to increase StO2 above 80%. However, these findings do not rule out a potential benefit of targeting StO2 in a different protocol based on different cut-off values, or different treatment strategy. Likewise, these findings did not rule out a potential benefit of targeting other surrogates of microcirculation.
Comment: Similarly, during the first 6 hours of the trial, there were no significant differences between the two study groups in any of the hemodynamic variables or lactate levels. StO2 were, at most, marginally reduced in the experimental arm and the only statistically significant difference could be due to multiple testing ( Table 2 ). The discussion appropriately distinguishes the issue of predictive validity of low StO2 from effectiveness of the interventions used in an attempt to raise StO2.
Response: In contrast with ScvO2 which baseline value was above 70% in roughly 70% of the patients, StO2 values were dramatically reduced at baseline in 2/3 of patients. Likewise, lactate levels were high and the P/F ratio low, both highlighting that the patients remained at baseline very sick and likely under-resuscitated. The fact that there was no difference overtime between the two arms highlighted that the StO2-guided strategy was not superior to the control strategy.
Reviewer 5
Comment: In abstract, results and discussion, focus on the stopping of the study. I suggest that the authors report on the reasons for low recruitment and explore the potential harms and not report the results as if this was a completed trial.
Response: We have made very transparent that the trial was stopped early. We have now added a paragraph in the discussion section explaining the reason for the arly termination of the study and how this may have impacted its findings.
Comment: I would like more information surrounding the stopping of the trial. It would be informative to have the report from the DSMB, and the statement from the trial management team, and the report to the IRB regarding the stopping of the study. Response: As mentioned above, the reason for the early termination of the trial was the decision of the sponsor to cease supporting the trial owing to the svere difficulties the company was faced with during the 2009 global economic crisis. This information has been corrected in the revised manuscript. The statistical plan did not include interim analysis, and the DSMB did not request interim analysis nor warned about any signal for harm. Then, it was only after the trial was stopped and data were available for analysis by an independent statistician that potential harms from experimental intervention were detected.
Comment: The tables of values of the trial at the time the study was stopped are reported as if the study was not stopped.
Response: We have added to all tables, a raw mentioning the expected number of patients for each study arm, followed by a raw with the actual number of patients Comment: The study may be underpowered, and I suggest that these tables be removed. If there is data that may be useful in designing future studies, this data should be presented with this purpose in mind, and should clearly be labelled as to its potential use.
Response: We have discussed in the revised manuscript, in the discussion section the impact of the eraly termination of the trial on the interpretation of the data. We strongly believed that it is important to report these data owing to the signal for potential harm.
Comment: The attached final report is by a statistician Stacia Krause, and the reviewer wonders why the statistician is not listed as an author of the paper.
Response: The statistical analysis has been done by an independent statistician selected and paid by the sponsor. The statistician did not request being an author. We have added the statistician in the acknowledgment section.
Comment: I would like to see evidence that the device works in the background section, and a reporting on the accuracy of the device measurements in the methods section. Has the device been tested in other settings?
Response: We have now added more information in the background section about the clinical use of NIRS derived StO2 in acutely ill patients We have added in the method section data on accuracy of measurements.
Comment: Why was this new device used in this severely ill population?
Response: NIRS-derives StO2 measurements has been commonly use in critically ill patients (see Neto et al 2014)
Comment: A histogram of the differences in the SOFA scores -were there any improvements?
Response: There was no evidence for a statistical significance between the two groups for SOFA scores from baseline to day -7 (these data have been added as a supplementary appendix) Table summarizes daily SOFA scores across treatment groups. Three patients, of which only one was randomized (10311, 10312, and 10429) did not have any SOFA data at the time of this report and are therefore not included in this table. The mean difference between study arms (StO2 -Control) in the change from baseline to Day 7 was 1.12 (95% CI= -0.996, 3.237; p-value=0.295). The difference obtained used only patients with a Baseline and Day 7 SOFA score. Table summarizes SOFA scores using the last value carried forward method. For patients without a Day 7 SOFA score the last known SOFA value was used for the calculation of the difference. Eight patients did not have a Baseline SOFA score so the Day 1 value was used as the Baseline score. The mean difference between study arms (StO2 -Control) in the change from baseline to Day 7 was 0.576 (95% CI= -1.272, 2.424; p-value=0.537). Comment: "This trial was terminated prematurely" -is this a statement suggesting that the study was stopped too early, or do you just mean the study was stopped due to lack of recruitment and harm, or do you believe it was stopped too early. If so, please state reasons why the authors feel it was stopped too early.
Response: The trial was stopped early because the trial sponsor was severely affected by the 2009 global economic crisis, and decided to stop supporting the trial. Thi decision was made prior to any analysis of data.
Comment: Missing data for the primary outcome -8 participants did not have the baseline SOFA score, and one did not have 7 day SOFA score. I suggest this is mentioned in the manuscript.
Response: We have now clearly reported for each outcome missing values and we have explained in the method section how we dealt with missing outcomes.
Comment: Confused about mention of non-randomised patients in report. Please do not report any data on non-randomised patients in the main tables, but put in a separate table, and discuss why this study had non-randomised patient data.
Response: In two centers, one patient died after consent was obtained from next of kin but before randomization.
Comment: There is mention in the attached report about no interim analysis -but manuscript mentions that it was stopped on second interim analysis.
Response: This was a mistake. The statistical plan did not include interim analysis. The trial was stopped for cessation of support from the sponsor as a consequence of budget constraints. This point is now clarified in the revised manuscript.
Comment: I knew SOFA as sequential organ failure assessment score, so was slightly thrown off by alternative name. Suggest using both unless it is very commonly known to be both. Response: As suggested, we have added in the discussion section some arguments for the selection of the primary outcome . A major objective of the initial resuscitation of patients with sepsis is to prevent the deterioration of organs function. The SOFA score has been proven to be an effective method to describe organ dysfunction/failure in critically ill patients. Regular, repeated scoring enables patient condition and disease development to be monitored and it may enable comparison between patients that would benefit clinical trials (see Vincent et al Critical Care Medicine 1998) . In addition, beside maximal total SOFA score, the delta SOFA score can be used to quantify the degree of dysfunction/failure already present on ICU admission, the degree of dysfunction/failure that appears during the ICU stay and the cumulative insult suffered by the patient. These properties make it a good instrument to be used in the evaluation of organ dysfunction/failure (see Moreno et al Intensive Care Medicine 1999) . Patients with increase by 1 point in SOFA score during the first days of ICU had death rates of >50% which were markedly higher than those of patients in whom the SOFA score decreased by 1 point (mortality 23%) or remained unchanged (mortality 31%) (see Ferreira et al JAMA 2001 Response: We have provided this information in the method section of the revised mansucript : « The randomisation (in a 1:1 ratio) was stratified according to the study centre, balanced by blocks of 4, and utilized a computerized random number generator list provided by an independent statistician.
Comment: The study may or may not have been done in the appropriate population. The reviewer is not sure that the device was appropriate for this severely ill population. It would be helpful if more details about these design issues were addressed.
Response: As mentioned in the background section, there was evidence that StO2 values in patients with sepsis/septic shock may be good predictor of poor outcomes. Several studies, including studies from our group, suggested that patients with sepsis have decreased StO2 as compared to healthy volunteers, and that the lower the StO2 value the greater the risk of death (see neto et al 2014). StO2 is considered as a surrogate for microcirculation. The selected population had obviously dramatically decreased baseline StO2 values, an thus, constituted the appropriate target population to investigate the benefit to harm ratio of StO2 guided resuscitation.
Comment: Justification for the choice of a "20% difference in the main criterion given" was not given for the clinical significant difference used in the sample size.
Response: Previous studies have shown that the absolute difference in mortality between ICU patients with increased SOFA score by 1 point or more overtime versus those with decreased or unchanged SOFA, was of 20%. (Ferreira et al JAMA 2001) .
Comment: The description of the differences in the treatment in each arm of the study needs to be clearer. The reviewer did not receive the initial protocol.
Response: We have now provided the original and final versions of the protocol as a supplementary appendix Comment: The reviewer is not sure of the use of a change of one in the SOFA, there is no discussion or support for this outcome.
Response: As suggested, we have added in the discussion section some arguments for the selection of the primary outcome (A major objective of the initial resuscitation of patients with sepsis is to prevent the deterioration of organs function. The SOFA score has been proven to be an effective method to describe organ dysfunction/failure in critically ill patients. Regular, repeated scoring enables patient condition and disease development to be monitored and it may enable comparison between patients that would benefit clinical trials (see Vincent et al Critical Care Medicine 1998). In addition, beside maximal total SOFA score, the delta SOFA score can be used to quantify the degree of dysfunction/failure already present on ICU admission, the degree of dysfunction/failure that appears during the ICU stay and the cumulative insult suffered by the patient. These properties make it a good instrument to be used in the evaluation of organ dysfunction/failure (see Moreno et al Intensive Care Medicine 1999) . Patients with increase by 1 point in SOFA score during the first days of ICU had death rates of >50% which were markedly higher than those of patients in whom the SOFA score decreased by 1 point (mortality 23%) or remained unchanged (mortality 31%) (see Ferreira et al JAMA 2001) .
Comment: The study is reported as if it was completed. It needs to be reported as stopped, and the results are the reasons and descriptions of lack of recruitment, and descriptions of the potential harms.
Response: We have made very transparent that the trial was stopped early. We have now added a paragraph in the discussion section explaining the reason for the arly termination of the study and how this may have impacted its findings. Comment: Not all of the endpoints listed in the report are listed in the paper. The secondary endpoints are listed were listed as 30 day mortality, ICU and hospital mortality, number of days alive and 1) off artificial ventilation, and ii) off catecholamines, and ICU and hospital length of stay.
Response: We apologize for not reporting all planed endpoints. We have now provided data for outcomes strictly according to the initial statistical plan
Comment: "The data and safety monitoring board recommended stopping enrollment after the second interim analysis due to low recruitment rate and safety concern. Although this study was underpowered to show an effect on the primary endpoint due to the premature early termination and difficulties encountered, it highlights practical issues to inform future studies." Other statements about the outcomes are questionable, unless there was enough power.
Response: We apologize for the confusion in the manuscript. As mentioned on clinicaltrials.gov, the trial was stopped following the decision of the sponsor to cease supporting the trial. Indeed, trial sponsor was severely affected by the economic crisis and reoriented its development strategy. The decision was taken before knowing about potential harm, as the statistical plan did not include interim analysis. The DSMB never detected any signal for arm and never requested to perform an interim analysis Comment: the missing data was not mentioned in the results or in the study limitations. Also, a large percentage of the patients screened were excluded, this needs to be addressed.
Response: This information has been added in the discussion section, as a study limitation Comment: There is zero lost to follow up mentioned in the CONSORT -but the report says that there was one person who did not have SOFA score, and eight that did not have baseline score -was this data found after the report?
Response: Patients were not lost to follow up to day 7 (time point for the primary outcome) even though for some patients actual SOFA score could not be computed due to missing data.
Comment: I am worried about the clinicaltrial.gov site not mentioning harm.
Response: We will report on clinicaltrial.gov all the results following the main publication. At time the trial was stopped for budget constraints the analyses were not yet performed 
